Effect of synthetic neuromedin C, a decapeptide of gastrin-releasing peptide (GRP [18-27]), on blood flow and exocrine secretion of the pancreas in dogs.
Neuromedin C, the smaller molecular form of gastrin releasing peptide (GRP [18-27]), has been recently identified from canine intestinal muscle and porcine spinal cord. This study was conducted to determine if this newly identified peptide retains biological activity on canine pancreas in vivo. Intravenous injection of graded doses of synthetic Neuromedin C caused a marked increase of systemic blood pressure and initial reduction of pancreatic blood flow in eleven anesthetized dogs, as measured by Laser Doppler Flowmetry. Flow volume and protein output of pancreatic juice were also increased by Neuromedin C in a dose-related manner in six dogs. These results suggest that this peptide is one of the biologically active forms of mammalian bombesin-like peptides and may possess physiological significance as a novel neuropeptide.
D000595:Amino Acid Sequence; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001839:Bombesin / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D019886:Gastrin-Releasing Peptide; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*; D010179:Pancreas / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism; D010446:Peptide Fragments; D010455:Peptides / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D014463:Ultrasonography
D009842:Oligopeptides; D010446:Peptide Fragments; D010455:Peptides; D019886:Gastrin-Releasing Peptide; C040794:neuromedin C; D001839:Bombesin